That sounds like a very healthy attitude elly.elly wrote:I need to say that i do like to hear anything positive about ms...anything that can give me hope that a good outcome is a possibility.
No matter what the statistics say etc i choose to believe that i will be fine, even if that's somewhat naive. I'm certainly not going to go out and buy a wheelchair in case i need one in 20 years. I'm not planning for the worst.
Not that there is even one good thing about having MS but fair or unfair, that's the reality you find yourself in and as far as can be proven, you only are going to have this one life to live. Your only real choices are to do your best to enjoy your one life, or let MS win.
Obviously through the years there have been lots of people with MS who have passed on and some of those records available to researcher were evidently detailed enough to document the way the disease presented itself in the beginning and disease course through the years. When it comes to MS, one example means nothing, 50 doesn't mean much, the average of a thousand is starting to present pretty good evidence but NOTHING can predict an individual's disease course with certainty.elly wrote:I would like to know where they get this information from...do they make it up as they go along or is it something that has been researched and these are the results.
Actually it's kind of nice to think that there probably will be a satisfactory resolution for MS long before they can accurately predict it's course in an individual.
You might find this interesting http://tinyurl.com/2jntyg
2007 May 8;
Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis.
BACKGROUND: Multiple sclerosis is a chronic disease of uncertain aetiology. Variations in its disease course make it difficult to impossible to accurately determine the prognosis of individual patients. The Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR) developed an "online analytical processing (OLAP)" tool that takes advantage of extant clinical trials data and allows one to model the near term future course of this chronic disease for an individual patient. RESULTS: For a given patient the most similar patients of the SLCMSR database are intelligently selected by a model-based matching algorithm integrated into an OLAP-tool to enable real time, web-based statistical analyses. The underlying database (last update April 2005) contains 1,059 patients derived from 30 placebo arms of controlled clinical trials. Demographic information on the entire database and the portion selected for comparison are displayed. The result of the statistical comparison is provided as a display of the course of Expanded Disability Status Scale (EDSS) for individuals in the database with regions of probable progression over time, along with their mean relapse rate. Kaplan-Meier curves for time to sustained progression in the EDSS and time to requirement of constant assistance to walk (EDSS 6) are also displayed. The software-application OLAP anticipates the input MS patient's course on the basis of baseline values and the known course of disease for similar patients who have been followed in clinical trials. CONCLUSION: This simulation could be useful for physicians, researchers and other professionals who counsel patients on therapeutic options. The application can be modified for studying the natural history of other chronic diseases, if and when similar datasets on which the OLAP operates exist.